TTK Healthcare Ltd. Stock Falls to 52-Week Low of Rs.929

Stock Price Movement and Market Context

On 13 Feb 2026, TTK Healthcare’s shares hit an intraday low of Rs.929, representing a 2.32% drop during the trading session. The stock has been on a downward trajectory for the past two days, losing 0.63% cumulatively in that period. Despite this, it marginally outperformed its sector by 0.53% today. The current price is substantially below the stock’s 52-week high of Rs.1402, indicating a decline of approximately 33.7% from that peak.

TTK Healthcare is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum. This contrasts with the broader market, where the Sensex, despite a negative opening and a fall of 1.25% to 82,626.76 points, remains only 4.27% below its own 52-week high of 86,159.02. The Sensex’s 50-day moving average remains above its 200-day average, suggesting a more stable medium-term trend compared to TTK Healthcare’s stock.

Financial Performance and Growth Trends

TTK Healthcare’s long-term growth has been modest, with net sales increasing at an annualised rate of 6.99% over the past five years. Operating profit has grown at a slightly higher rate of 15.42% during the same period. However, these figures have not translated into strong stock performance, as evidenced by the company’s 1-year return of -22.98%, which significantly underperforms the Sensex’s 8.52% gain over the same timeframe.

Quarterly and half-yearly financial indicators also reflect subdued momentum. The company’s cash and cash equivalents stood at Rs.600.89 crores at the half-year mark, the lowest level recorded in recent periods. Additionally, the debtors turnover ratio has declined to 7.40 times, indicating slower collection efficiency. Non-operating income accounted for 80.43% of profit before tax in the latest quarter, suggesting that core business profitability remains under pressure.

Valuation and Market Perception

TTK Healthcare’s valuation metrics present a mixed picture. The company maintains a low average debt-to-equity ratio of zero, reflecting a conservative capital structure. Its return on equity (ROE) stands at 6.5%, which is moderate but not indicative of high profitability. The stock trades at a price-to-book value of 1.2, which is a premium relative to its peers’ historical averages.

Despite the company’s size, domestic mutual funds hold a minimal stake of just 0.01%. Given that mutual funds typically conduct thorough research before investing, this limited exposure may reflect reservations about the company’s current valuation or business prospects. Over the past year, while profits have increased marginally by 2.4%, the stock’s price decline of nearly 23% has resulted in a high price/earnings to growth (PEG) ratio of 8.1, signalling that the stock may be overvalued relative to its earnings growth.

Comparative Performance and Ratings

TTK Healthcare’s performance has lagged behind broader market indices and sector benchmarks over multiple time horizons. The stock has underperformed the BSE500 index over the last three years, one year, and three months. This underperformance is reflected in its current Mojo Score of 37.0 and a Mojo Grade of Sell, downgraded from Hold on 21 Jul 2025. The company’s market cap grade is rated 4, indicating a mid-tier market capitalisation within its sector.

On the day of the new 52-week low, the stock’s price declined by 0.54%, continuing a trend of subdued investor sentiment. The broader Sensex’s decline of 1.25% on the same day highlights a challenging market environment, but TTK Healthcare’s relative underperformance remains notable.

Summary of Key Metrics

To summarise, TTK Healthcare Ltd. has experienced a significant decline to Rs.929, its lowest price in the past 52 weeks. The stock’s performance over the last year has been negative at -22.98%, contrasting with the Sensex’s positive 8.52% return. The company’s growth rates for net sales and operating profit remain modest, while cash reserves and debtor turnover ratios have weakened. The stock trades below all major moving averages and carries a Sell rating with a Mojo Score of 37.0.

While the company’s low debt and moderate ROE provide some stability, the premium valuation relative to peers and limited mutual fund interest highlight ongoing concerns. The stock’s recent price action and financial indicators suggest a cautious stance among market participants.

Unlock special upgrade rates for a limited period. Start Saving Now →